Articles from Curi Bio

Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round. The round was led by DreamCIS, the leading contract research organization based in Seoul, South Korea, offering comprehensive services for clinical research and regulatory affairs. This strategic partnership is poised to accelerate the translation of Curi Bio's human-relevant platforms into global clinical success.

Curi Bio, the global leader in human 3D engineered tissue platforms, and Cook MyoSite, a pioneer in the development of skeletal muscle-based therapies, today announced a strategic partnership to develop advanced, predictive human engineered tissue models aimed at addressing muscle-related diseases and metabolic disorders, including obesity and diabetes.

Curi Bio, the industry leader in delivering human functional data to the drug discovery community, marked a significant milestone with the official ribbon-cutting ceremony at its new global headquarters located at BioMed Realty’s 201 Elliott Avenue West in Seattle. Held on Thursday, April 3, 2025, the event showcased the company’s newly constructed 13,942-square-foot labs and facility. The new headquarters is designed to support Curi Bio’s growth and continued mission to accelerate innovation in preclinical drug development by unlocking functional human data to inform biopharmaceutical R&D decision making.

Curi Bio, the industry leader in delivering human functional data to the drug discovery community, and Novoheart, maker of the industry’s most sophisticated and comprehensive human cardiac tissue engineering platforms, today announced the integration of Novoheart’s MyHeart™ human ventricular cardiac organoid chamber (hvCoC) platform, also known as the “Human Heart-in-a-Jar,” into Curi Bio’s proprietary cloud-based Pulse™ analysis platform. Through this collaboration and joint commercialization, this advancement enables users of Novoheart’s advanced hvCoC to analyze their data directly into Curi Bio’s Pulse analytics platform, providing biopharmaceutical researchers with deeper, actionable insights into cardiac drug development and disease modeling.

Curi Bio, a leader in delivering human functional data to drug discoverers through advanced preclinical tissue models, is proud to announce its selection as one of Deloitte's Technology Fast 500™ companies in 2024, an annual ranking of the 500 fastest-growing technology companies in North America. Curi Bio achieved an overall rank of #123 and secured #18 out of the 70 life sciences companies recognized, highlighting its transformative contribution to enabling the development of next-generation medicines. Curi Bio’s innovative human stem cell platforms deliver functional data that enable biopharmaceutical researchers to make better informed, data-driven decisions during preclinical drug development.

Curi Bio, the industry leader in developing human stem cell-based platforms for drug discovery, is proud to announce the signing of a seven-year lease for a 13,942-square-foot space at BioMed Realty’s 201 Elliott Avenue West in Seattle. This strategic expansion will enable Curi Bio to expand its research and development efforts, advancing its mission to unlock critical human data that informs biopharmaceutical R&D decision-making.

Curi Bio, the industry leader in developing human stem cell-based platforms for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) for scientific and strategic collaboration with Genetox and DreamCIS. Genetox, an emerging biopharmaceutical company specializing in the sale and manufacture of botulinum toxin (BoT) for cosmetic and therapeutic purposes, and DreamCIS, a leading provider of CRO services supporting clinical development and regulatory affairs, will collaborate with Curi Bio to use the company’s cutting-edge neuromuscular junction (NMJ) model as a non-animal potency assay for advancing Genetox’s BOTAONE (botulinum toxin) through US FDA approval.

Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of its Nautilus™ and Stingray™ platforms for advancing preclinical drug discovery. With Nautilus, researchers can now interrogate the electrophysiology of their 2D or 3D cell cultures using the latest optical measurement techniques at the push of a button. The Stingray platform allows for maturation of 3D tissues via electrical stimulation with a level of versatility currently unmatched in the industry. As an integrated part of Curi Bio’s growing ecosystem of preclinical human modeling platforms, these innovative technologies promise to transform the way researchers can assess physiologically relevant data such as safety and efficacy earlier in the drug discovery process.

Curi Bio, the industry leader in developing human stem cell-based platforms for drug discovery, proudly announces two recent SBIR grants worth $4.4 million from the National Institutes of Health (NIH) to support its pioneering work on implementing human models to advance discovery of the next generation of medicines. The first project will support expansion of Curi’s cutting-edge in vitro human muscle platform by developing mouse model engineered muscle tissues (EMTs) to bridge the inconsistencies between animal and human data. The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics. These grants, the first of their kind received by Curi Bio from the National Center for Advancing Translational Sciences (NCATS), demonstrate the impact that the company's innovative 3D tissue platforms have made in developing new medicines. These latest awards bring the total non-dilutive funding that Curi Bio has received from the NIH to over $12 million.

Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReadyTM iPSC-Derived Skeletal Muscle Myoblasts specifically optimized for creating human 3D engineered muscle tissues for preclinical therapeutic discovery, high-throughput screening, and disease modeling.

Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReady™ Skeletal Muscle Media optimized for human 3D engineered muscle tissue experiments. The proprietary media advances translational in vitro studies by producing tissues with stronger contractile forces, faster kinetics, and greater longevity compared to tissues cultured in conventional or other commercially available differentiation media. With this commercial launch, these media will be available in Primary and iPSC skeletal muscle media kits, including differentiation and maintenance formulas, targeting all stages of muscle development and maturation.

Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the appointment of Nicholas A. Geisse, Ph.D. as Chief Executive Officer, effective immediately. Dr. Geisse has been serving as the Chief Science Officer at Curi Bio since 2017. During that time, he was responsible for guiding the company’s scientific strategy and the commercialization of its next-generation products that greatly improve the predictive power of in vitro cell-based assays. Dr. Geisse succeeds Michael Cho, J.D., who will continue on with the company in a role focusing on corporate strategy and legal matters.

Curi Bio is proud to announce that Co-founder and Chief Business Officer Elliot Fisher has been listed as one of Forbes 30 Under 30 in healthcare.

Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of the Mantarray™ platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis. Curi’s Mantarray platform enables the discovery of new therapeutics by providing parallel analysis of 3D EMTs with adult human-like functional profiles of healthy and disease models. Over the past three years, Curi Bio has developed the Mantarray platform in close beta testing and development partnerships with several leading global pharma companies, biotech companies, and regulatory agencies for use in their drug discovery and development projects. With this commercial launch, the Mantarray instrument and consumables will be available worldwide, on a first-come, first-served basis.

Curi Bio, a leading developer of human stem cell-based platforms and technologies for drug discovery, today announced the exclusive commercial acquisition from StemBioSys of the CarTox™ technology platform for calcium and voltage optical mapping. In parallel, Curi Bio announced it will commercialize the technology through its newly announced product: the Nautilus™ optical mapping system. By providing drug developers with human-relevant tissue-specific biosystems in the preclinical stage of drug development, Curi helps pharmaceutical partners develop safer, more effective therapeutics.

Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA.